Venture is where the next decade’s value gets built. That was the core message of Lukas Weber’s keynote at our Key Investor Event 2026 in Zurich. The Verve co-founder explained why a faster-changing world needs more venture capital, why deep tech is back, and how AI is speeding up every sector.
- Why venture matters more in a world that changes faster, and why the next champions will be built on technology
- Where the future is built: deep tech, AI as the big accelerator, and the three verticals Verve invests in
- The 2026 review: five exits in 18 months, the FINMA securities firm license and the first closing of Verve Venture Fund II
Why Venture, and Why Now
The world is changing faster, and even the largest companies cannot count on staying on top. The average time a company stays in the S&P 500 has fallen from 61 years in 1958 to about 15 years today, according to Apollo Academy and the Innosight Corporate Longevity Forecast. That is close to the lifespan of a venture fund. Today’s incumbents will be replaced, and the companies that replace them have to be built first.
Public markets are only part of the picture. Global private markets assets under management grew from about $1 trillion in 2003 to $13.1 trillion in 2023, according to the McKinsey Global Private Markets Report. Private equity has opened up steady cash flows outside the stock exchange. But the faster the world changes, the fewer companies keep stable cash flows, which is why Lukas expects venture to gain importance.
He described a pull and a push. The pull comes from big challenges in energy, health, security and resources that incremental improvements will not solve. The push comes from science reaching products faster, from far more fields that venture can now back, and from top talent choosing startups.
Technology Wins: Building Switzerland’s Next Champions
Switzerland shows both how stable things have been and how much room there is. The ten largest companies in the SMI, from Novartis and Nestlé to ABB and Roche, are all more than a century old. Lukas sees an opportunity in adding a few new “golden dots” to that picture, and he expects them to grow out of technology.
Technology is the conviction Verve was founded on. If something is simply better, people use it and keep using it, and that changes how people live and how companies work. The investors in the room agree: in a recent survey, 71% named innovation and emerging technologies as a main driver for investing in venture.
Every wave of technology was feared at first, Lukas reminded the audience, from industrialization to the car and the computer. AI is the latest example, and as a father he understands the worry. His conclusion: the people and investors who embrace change and accept the risk of new companies end up on the bright side of the future.
Verve’s portfolio shows what that looks like. Memo Therapeutics develops new antibody medicines, Aylight is solving the AI bottleneck with lasers, Neustark stores CO2 in recycled concrete, Orakl Oncology is transforming cancer drug discovery, and tozero recovers critical raw materials from lithium-ion batteries. These are just some examples of the current Verve portfolio companies.
Deep Tech Is Back, and AI Is the Accelerator
Silicon Valley started in deep tech. Semiconductors came first, then Apple and Genentech and the era of biotech. Only later did the internet and software take the limelight, because they dominated our lives for the past 20 years. Lukas’s point: deep tech is back, and Verve saw it early. When Verve started in 2010, one of its first investments was in semiconductors. In 2015 it went all in on areas that many then called too complicated.
AI accelerates this shift well beyond software. Lukas gave three examples. Mineral discovery that used to take five to ten years now takes around one and a half years, as at portfolio company Atana. Drug discovery that took about six years can now be done in under 18 months in some cases. And the industry is testing whether end-to-end chip design can shrink from two to three years to a matter of weeks.
Three Verticals and Europe’s Research Edge
Europe’s research is globally leading in health & bio, computing, and energy & resources, and Verve has spent 16 years building the network that brings it close to these universities. Lukas said it is the team’s job to find the entrepreneurs behind this research early. Today Verve invests along three verticals. Future computing covers the full stack behind AI, from new materials and photonics to quantum and software. Health & bio is, in Lukas’s view, probably Europe’s most interesting applied AI field. Energy & resources is what will let industry and AI win, because both depend on stable electricity and materials.
Three portfolio companies illustrate them. NcodiN replaces copper with light inside chips, using the world’s smallest laser integrated on silicon. Orakl Oncology builds predictive models for cancer from a library of “tumor avatars” that combine live biology with patient data. Sizable Energy takes pumped hydro energy storage offshore, a concept that gains relevance as people start to plan data centers in the ocean.
Each vertical has its own lead on the Verve team, Emma Schepers for Future computing, Xavier Mesnier for Health & Bio and Thomas Meier for Energy & Resources.
Access and the Power Law
In venture, a small share of companies drives most of the returns. 10% of the companies in a portfolio deliver 90% of the returns. Miss the one or two companies that make the difference, and the portfolio will not look good. Nobody knows upfront which ones they will be, so a portfolio needs 10 to 20 companies of the right quality.
That makes access the central question. It takes a lot of work to find these companies and to get into their rounds. In a recent survey among Verve’s investor clients, access to rounds that investors cannot reach alone was what they valued most about working with Verve.
2026 in Review
Verve counted five strong exits over the last 18 months. In 2025, Beekeeper joined forces with LumApps, a Bridgepoint portfolio company. WeMaintain saw Otis take a majority stake, and Ikerian, the AI-powered retina scan company, was acquired by EssilorLuxottica. In 2026, Lexroom had a partial secondary sale, and Memo Therapeutics, the largest position in Verve’s flagship fund, was acquired by Ipsen. The deal was announced by Ipsen in July 2026, with total potential consideration of up to more than €700 million.
Over 16 years, Verve has realized more than 30 exits, and assets under management have grown to over CHF 400 million across a portfolio of more than 120 companies. This year Verve also obtained its FINMA securities firm license, a level of regulation just below banks. For something as inherently risky as venture capital, Lukas said, it was important to build a foundation that is worthy of investors’ capital.
In July 2026, Verve completed the first closing of Verve Venture Fund II, which focuses on companies at pre-seed and seed stage.
The Bigger Picture
When Lukas Weber and his co-founder Steffen Wagner started Verve 16 years ago, the mission was to find companies with the potential to change the world and to build new cornerstones of the economy. After a few failures and some real successes that are now starting to materialize, that mission still holds, and the team is more excited than ever. The closing slide of the keynote put it in one line: the future is built by people like you, the entrepreneurs who put everything into one company and the investors who back them before it is obvious.
Written by
Investors

Our sophisticated investors include visionary family offices, leading wealth managers, institutions, founders, and senior executives. These individuals and organizations are all committed to shaping the next generation of innovation.
More News
Resilience in Energy & Resources – Webinar Recording
Missed our Energy & Resources webinar? Watch the recording. Lorenzo Fabritius unpacks Verve's updated thesis on energy, resources and industrial resilience, with the market data behind it. Metafuels and Encosa Energy join to show what building in this space looks like in practice.
Verve Ventures secures FINMA securities firm license
This milestone establishes Verve as a pioneer in the venture capital landscape, elevating the firm into the top tier of regulated financial institutions in Switzerland. The license provides an institutional-grade bridge for private and professional investors to access high-growth European technology investments with unparalleled structural security.
Memo Therapeutics to be acquired by global biopharma leader Ipsen
A landmark exit for European biotech: Memo Therapeutics AG enters a definitive agreement to be acquired by global biopharma leader Ipsen for a total potential consideration in excess of €700 million, advancing first-in-class antibody potravitug toward pivotal trials for kidney transplant patients. you copy paste please use the Text Tab to avoid unwanted text-formats.


